2020 ASCO Virtual Direct™ Highlights


 

2020 ASCO Highlights on Esophageal & HCC: CRT + Trastuzumab vs. CRT in Esophageal and GE Junction Adenocarcinomas, Trastuzumab/Pertuzumab to FLOT, Donafenib vs. Sorafenib in 1L Advanced HCC

112 views
September 16, 2020
Comments 0
Login to view comments. Click here to Login